Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease

NMR in Biomedicine

Volumn 20, Issue 8, 2007, Pages 709-716

  Griffith, H Randall ^a,b,c   den Hollander, Jan A ^c   Stewart, Chris C ^c   Evanochko, William T ^c   Buchthal, Steven D ^c   Harrell, Lindy E ^a,b   Zamrini, Edward Y ^a,b   Brockington, John C ^a,b   Marson, Daniel C ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aged; Brain metabolism; Dementia; Mild cognitive impairment; Spectroscopy

Indexed keywords

BIOMEDICAL ENGINEERING; MAGNETIC RESONANCE IMAGING; METABOLISM;

ALZHEIMER'S DISEASE; BRAIN METABOLISM; MILD COGNITIVE IMPAIRMENT; SCYLLO-INOSITOL CONCENTRATIONS;

BRAIN;

CREATINE; DONEPEZIL; GALANTAMINE; INOSITOL; N ACETYLASPARTIC ACID; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN BIOPSY; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WECHSLER MEMORY SCALE;

AGED; ALZHEIMER DISEASE; ASPARTIC ACID; BIOPSY; BRAIN; COGNITION DISORDERS; CREATINE; FEMALE; HUMANS; INOSITOL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; REFERENCE VALUES;

EID: 37349017232     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1132     Document Type: Article

References (44)

1. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000; 355: 1696-1697.
2. Watanabe T, Akiguchi I, Yagi H, Onishi K, Kawasaki T, Shiino A, Inubushi T. Proton magnetic resonance spectroscopy and white matter hyperintensities on magnetic resonance imaging in patients with Alzheimer's disease. Ann N YAcad Sci 2002; 977: 423-429.
3. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 2002; 59: 955-962.
4. 1H-MRS at 0.5T. Neurology 2001; 56: 737-742.
5. Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002; 13: 183-186.
6. Herminghaus S, Frolich L, Gorriz C, Pilatus U, Dierks T, Wittsack HJ, Lanfermann H, Maurer K, Zanella FE. Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. Psychiatry Res 2003; 123: 183-190.
7. 1H MRS study. Neurology 2000; 55: 210-217.
8. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 2002; 125: 2332-2341.
9. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, Lamerichs R, Henn R, Schild HH. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55: 684-688.
10. Weiss U, Bacher R, Vonbank H, Kermnler G, Lingg A, Marksteiner J. Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. J Clin Psychiatry 2003; 64: 235-242.
11. Waldman AD, Rai GS, McConnell JR, Chaudry M, Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 2002; 35: 137-142.
12. 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004; 1003: 26-35.
13. Sherman WR, Stewart MA, Kurien MM, Goodwin SL. The measurement of myo-inositol, myo-inosose-2 and scyllo-inositol in mammalian tissues. Biochim Biophys Acta 1968; 158: 197-205.
14. 1H magnetic resonance spectroscopy study at 4 Tesla. NMR Biomed 2005; 18: 51-55.
15. Michaelis T, Helms G, Merboldt KD, Hanicke W, Bruhn H, Frahm J. Identification of scyllo-inositol in proton NMR spectra of human brain in vivo. NMR Biomed 1993; 6: 105-109.
16. Frahm J, Bruhn H, Hanicke W, Merboldt KD, Mursch K, Markakis E. Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequences. J Comput Assist Tomogr 1991; 15: 915-922.
17. Meyerhoff DJ, Fein G, Weiner MW. Elevated scyllo-inositol in adult human brain. In: Proceedsings of ISMRM, 4th Scientific Meeting; 1996; New York; 1996; p. 954.
18. Viola A, Nicoli F, Denis B, Confort-Gouny S, Le Fur Y, Ranjeva JP, Viout P, Cozzone PJ. High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism. Magma 2004; 17: 47-61.
19. Lien YH, Michaelis T, Moats RA, Ross BD. Scyllo-inositol depletion in hepatic encephalopathy. Life Sci 1994; 54: 1507-1512.
20. 1H NMR spectra with increased magnetic field strength. J Magn Reson 1998; 135: 260-264.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
22. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
23. Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical guide for grading the cognitive state of the patient for the physician. J Psychiatry Res 1975; 12: 189-198.
24. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
25. Petersen RC, Doody R, Kurz A, Mobs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
26. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005; 62: 1160-1163; discussion 1167.
27. Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 1998; 64: 588-594.
28. Griffith HR, den Hollander JA, Okonkwo O, Evanochko WT, Harrell LE, Zamrini EY, Brockington JC, Marson DC. Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. J Clin Exp Neuropsychol 2007; in press.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-259.
30. Lamb HJ, Doombos J, den Hollander JA, Luyten PR, Beyerbacht HP, van der Wall EE, de Roos A. Reproducibility of human cardiac 31P-NMR spectroscopy. NUR Biomed 1996; 9: 217-227.
31. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 2001; 14: 278-283.
32. SPSSInc. SPSS Base 10. 0 Applications Guide. SPSS Inc: Chicago, 2000.
33. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13: 129-153.
34. Kantarci K, Smith GE, Ivnik RJ, Petersen RC, Boeve BF, Knopman DS, Tangalos EG, Jack CR Jr. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 2002; 8: 934-942.
35. Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002; 82: 736-754.
36. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem 2000; 275: 18495-18502.
37. Strange K, Emma F, Paredes A, Morrison R. Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 1994; 12: 35-43.
38. Brand A, Richter-Landsberg C, Leibftitz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-298.
39. Royall DR, Mulroy AR, Chiodo LK, Polk MJ. Clock drawing is sensitive to executive control: a comparison of six methods. J Gerontol B Psychol Sci Soc Sci 1999; 54: P 328-333.
40. Braak H, Braak E. Alzheimer neuropathology and limbic circuits. In Neurobiology of Cingulate Cortex and Limbic Thalamus, Vogt BA, Gabriel M (eds). Birkhauser: Boston, 1993; 606-626.
41. Baleydier C, Mauguiere F. The duality of the cingulate gyrus in monkey. Neuroanatomical study and functional hypothesis. Brain 1980; 103: 525-554.
42. Ouchi Y, Yoshikawa E, Futatsubashi M, Okada H, Torizuka T, Kaneko M. Activation in the premotor cortex during mental calculation in patients with Alzheimer's disease: relevance of reduction in posterior cingulate metabolism. Neuroimage 2004; 22: 155-163.
43. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
44. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005; 162: 667-675.